Lincoln National Corp purchased a new position in shares of Ocuphire Pharma, Inc. (NASDAQ:OCUP – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,600 shares of the company’s stock, valued at approximately $41,000. Lincoln National Corp owned approximately 0.06% of Ocuphire Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently bought and sold shares of OCUP. Richmond Brothers Inc. boosted its holdings in shares of Ocuphire Pharma by 3.0% during the third quarter. Richmond Brothers Inc. now owns 320,332 shares of the company’s stock worth $641,000 after purchasing an additional 9,212 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Ocuphire Pharma during the second quarter worth about $381,000. Millennium Management LLC purchased a new stake in shares of Ocuphire Pharma during the second quarter worth about $68,000. Bank of Montreal Can purchased a new stake in shares of Ocuphire Pharma during the first quarter worth about $68,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Ocuphire Pharma during the third quarter worth about $51,000. Hedge funds and other institutional investors own 13.59% of the company’s stock.
Ocuphire Pharma Stock Up 1.8 %
Shares of Ocuphire Pharma stock opened at $6.35 on Friday. The firm has a market cap of $133.02 million, a P/E ratio of 8.36 and a beta of 0.32. Ocuphire Pharma, Inc. has a fifty-two week low of $1.78 and a fifty-two week high of $6.60. The business has a 50-day moving average price of $4.75 and a 200 day moving average price of $3.69.
Wall Street Analysts Forecast Growth
About Ocuphire Pharma
Ocuphire Pharma, Inc engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Read More
- Get a free copy of the StockNews.com research report on Ocuphire Pharma (OCUP)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Receive News & Ratings for Ocuphire Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocuphire Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
